Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/cancer-drug-price-hope-4681756/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/cancer-drug-price-hope-4681756/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/cancer-drug-price-hope-4681756/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/cancer-drug-price-hope-4681756/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-trace').style.display = (document.getElementById('cakeErr67eecfdebdcf4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eecfdebdcf4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-code').style.display = (document.getElementById('cakeErr67eecfdebdcf4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-context').style.display = (document.getElementById('cakeErr67eecfdebdcf4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eecfdebdcf4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eecfdebdcf4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33661,
		&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681756,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33661,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33661,
	&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681756,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33661
$metaTitle = &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;
$metaKeywords = &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/cancer-drug-price-hope-4681756.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Cancer drug price hope | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Cancer drug price hope</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br /><br />It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br /><br />The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br /><br />&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br /><br />If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br /><br />Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br /><br />&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br /><br />The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br /><br />In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br /><br />Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU" title="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-trace').style.display = (document.getElementById('cakeErr67eecfdebdcf4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eecfdebdcf4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-code').style.display = (document.getElementById('cakeErr67eecfdebdcf4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-context').style.display = (document.getElementById('cakeErr67eecfdebdcf4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eecfdebdcf4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eecfdebdcf4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33661,
		&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681756,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33661,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33661,
	&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681756,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33661
$metaTitle = &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;
$metaKeywords = &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/cancer-drug-price-hope-4681756.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Cancer drug price hope | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Cancer drug price hope</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br /><br />It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br /><br />The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br /><br />&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br /><br />If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br /><br />Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br /><br />&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br /><br />The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br /><br />In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br /><br />Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU" title="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-trace').style.display = (document.getElementById('cakeErr67eecfdebdcf4-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67eecfdebdcf4-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-code').style.display = (document.getElementById('cakeErr67eecfdebdcf4-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67eecfdebdcf4-context').style.display = (document.getElementById('cakeErr67eecfdebdcf4-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67eecfdebdcf4-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67eecfdebdcf4-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 33661,
		&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 4681756,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 33661,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 33661,
	&#039;title&#039; =&gt; &#039;Cancer drug price hope&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Telegraph&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;
&lt;br /&gt;
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;
&lt;br /&gt;
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;
&lt;br /&gt;
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;
&lt;br /&gt;
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;
&lt;br /&gt;
&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;
&lt;br /&gt;
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;
&lt;br /&gt;
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;
&lt;br /&gt;
Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;cancer-drug-price-hope-4681756&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 4681756,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {},
		(int) 4 =&gt; object(Cake\ORM\Entity) {},
		(int) 5 =&gt; object(Cake\ORM\Entity) {},
		(int) 6 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 33661
$metaTitle = &#039;LATEST NEWS UPDATES | Cancer drug price hope&#039;
$metaKeywords = &#039;world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines&#039;
$metaDesc = &#039;
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Telegraph&lt;br /&gt;&lt;br /&gt;&lt;em&gt;New Delhi: &lt;/em&gt;The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.&lt;br /&gt;&lt;br /&gt;It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin&#039;s lymphoma, and trastuzumab, used to treat breast cancer.&lt;br /&gt;&lt;br /&gt;The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.&lt;br /&gt;&lt;br /&gt;&amp;quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&amp;quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.&lt;br /&gt;&lt;br /&gt;If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.&lt;br /&gt;&lt;br /&gt;Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.&lt;br /&gt;&lt;br /&gt;&amp;quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&amp;quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &amp;quot;The entry of the generics and price control by the government have both helped reduce prices.&amp;quot;&lt;br /&gt;&lt;br /&gt;The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients&#039; groups and health policy makers.&lt;br /&gt;&lt;br /&gt;In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.&lt;br /&gt;&lt;br /&gt;Please &lt;a href=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot; title=&quot;https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU&quot;&gt;click here&lt;/a&gt; to read more. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/cancer-drug-price-hope-4681756.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Cancer drug price hope | Im4change.org</title>
    <meta name="description" content="
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Cancer drug price hope</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br /><br />It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br /><br />The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br /><br />&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br /><br />If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br /><br />Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br /><br />&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br /><br />The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br /><br />In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br /><br />Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU" title="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 33661,
		'title' => 'Cancer drug price hope',
		'subheading' => '',
		'description' => '<div align="justify">
-The Telegraph<br />
<br />
<em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br />
<br />
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br />
<br />
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br />
<br />
&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br />
<br />
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br />
<br />
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br />
<br />
&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br />
<br />
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br />
<br />
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br />
<br />
Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br />
</div>',
		'credit_writer' => 'The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'cancer-drug-price-hope-4681756',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 4681756,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 33661,
	'metaTitle' => 'LATEST NEWS UPDATES | Cancer drug price hope',
	'metaKeywords' => 'world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines',
	'metaDesc' => '
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...',
	'disp' => '<div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br /><br />It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br /><br />The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br /><br />&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br /><br />If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br /><br />Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br /><br />&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br /><br />The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br /><br />In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br /><br />Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU" title="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 33661,
	'title' => 'Cancer drug price hope',
	'subheading' => '',
	'description' => '<div align="justify">
-The Telegraph<br />
<br />
<em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br />
<br />
It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br />
<br />
The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br />
<br />
&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br />
<br />
If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br />
<br />
Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br />
<br />
&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br />
<br />
The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br />
<br />
In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br />
<br />
Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br />
</div>',
	'credit_writer' => 'The Telegraph, 5 May, 2017, https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'cancer-drug-price-hope-4681756',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 4681756,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {},
		(int) 4 => object(Cake\ORM\Entity) {},
		(int) 5 => object(Cake\ORM\Entity) {},
		(int) 6 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 33661
$metaTitle = 'LATEST NEWS UPDATES | Cancer drug price hope'
$metaKeywords = 'world health organisation,WHO,generic drugs,generic medicine,generic medicines,Cancer,Cancer Medicines'
$metaDesc = '
-The Telegraph

New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.

It said it would invite manufacturers to submit...'
$disp = '<div align="justify">-The Telegraph<br /><br /><em>New Delhi: </em>The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries.<br /><br />It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer.<br /><br />The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies.<br /><br />&quot;Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines,&quot; Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release.<br /><br />If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines.<br /><br />Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels.<br /><br />&quot;When domestic generic companies began making these medicines, the prices converged to lower levels,&quot; said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. &quot;The entry of the generics and price control by the government have both helped reduce prices.&quot;<br /><br />The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers.<br /><br />In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals.<br /><br />Please <a href="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU" title="https://www.telegraphindia.com/1170506/jsp/nation/story_150094.jsp#.WQ3pWtzhXIU">click here</a> to read more. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Cancer drug price hope

-The Telegraph New Delhi: The World Health Organisation has announced a plan to approve generic versions of two expensive bio-therapeutic anti-cancer molecules in an effort to make them available to low and middle-income countries. It said it would invite manufacturers to submit applications for pre-qualification of biologically similar versions of rituximab, used to treat chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, and trastuzumab, used to treat breast cancer. The pre-qualification process is a mechanism to certify that the generic versions of these bio-therapeutic molecules are pharmacologically similar to the more expensive products from innovator companies. "Innovator bio-therapeutic products are often too expensive for many countries, so bio-similars are a good opportunity to expand access and support countries to regulate and use these medicines," Marie-Paule Kieny, WHO assistant director-general for health systems and innovation, said in a media release. If the WHO finds that the bio-similars for pre-qualification are comparable to the originator products in terms of quality, safety and efficacy, it will list the medicines, which will become eligible for procurement by UN agencies. Many low and middle-income countries too rely on pre-qualification before procuring medicines. Cancer specialists in India say that generic versions of both rituximab and trastuzumab are already available in the country, and their entry into the market had forced a reduction in prices of the originator products to comparable levels. "When domestic generic companies began making these medicines, the prices converged to lower levels," said Raju Titus Chacko, professor of medical oncology at the Christian Medical College, Vellore. "The entry of the generics and price control by the government have both helped reduce prices." The WHO move for pre-qualification for the two anti-cancer bio-similars follows a two-day meeting in Geneva between its senior officials, national regulators, pharmaceutical industry representatives, patients' groups and health policy makers. In women with non-metastatic breast cancer that over-expresses a molecular receptor called HER2, the addition of trastuzumab to chemotherapy reduces mortality by over 30 per cent. Multiple clinical studies have suggested that even in metastatic cancer, the addition of trastuzumab is associated with increased overall survivals. Please click here to read more.